DOACs reduce dementia risk versus warfarin in A-Fib
Sep 07, 2023
Significant reductions were seen in dementia risk for rivaroxaban, apixaban and dabigatran versus warfarin in a network meta-analysis.
Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D
Dec 27, 2023
Dapagliflozin, however, does not reduce the urinary albumin-to-creatinine ratio in those patients.
Lixisenatide reduces motor disability progression in Parkinson’s disease
Apr 04, 2024
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
Minocycline does not decrease geographic atrophy enlargement in AMD
Mar 25, 2024
The GA enlargement rate in the study eyes did not differ significantly in the run-in and treatment phases in age-related macular degeneration.
Four JAK inhibitors have comparable efficacy, safety for RA
Dec 01, 2023
Baseline CRP, Clinical Disease Activity Index and glucocorticoid dose predict resistance to CDAI-low disease activity achievement.
Lorundrostat effective for lowering BP in uncontrolled hypertension
Sep 15, 2023
Changes in office systolic BP of −14.1, −13.2, −6.9 and −4.1 mm Hg were seen with 100, 50, 12.5 mg once daily of lorundrostat and placebo.
FDA approves Voquezna for erosive esophagitis, GERD
Nov 07, 2023
A Phase 3 trial showed noninferiority versus lansoprazole in healing and maintenance phases.
Medicare to cover Wegovy when patients also have heart disease
Mar 22, 2024
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Expanded use of Xolair to treat food allergies approved by the FDA
Feb 17, 2024
Xolair is not meant to substitute for emergency anaphylaxis medications such as the EpiPen.